Regulation of Intestinal Inflammation by Walnut-Derived Bioactive Compounds.
Kexin DaiNeel AgarwalAlexander Rodriguez-PalaciosAbigail Raffner BassonPublished in: Nutrients (2024)
Walnuts ( Juglans regia L.) have shown promising effects in terms of ameliorating inflammatory bowel disease (IBD), attributed to their abundant bioactive compounds. This review comprehensively illustrates the key mechanisms underlying the therapeutic potential of walnuts in IBD management, including the modulation of intestinal mucosa permeability, the regulation of inflammatory pathways (such as NF-kB, COX/COX2, MAPCK/MAPK, and iNOS/NOS), relieving oxidative stress, and the modulation of gut microbiota. Furthermore, we highlight walnut-derived anti-inflammatory compounds, such as polyunsaturated fatty acids (PUFA; e.g., ω-3 PUFA), tocopherols, phytosterols, sphingolipids, phospholipids, phenolic compounds, flavonoids, and tannins. We also discuss unique anti-inflammatory compounds such as peptides and polysaccharides, including their extraction and preparation methods. Our review provides a theoretical foundation for dietary walnut supplementation in IBD management and provides guidance for academia and industry. In future, research should focus on the targeted isolation and purification of walnut-derived anti-inflammatory compounds or optimizing extraction methods to enhance their yields, thereby helping the food industry to develop dietary supplements or walnut-derived functional foods tailored for IBD patients.
Keyphrases
- toll like receptor
- oxidative stress
- anti inflammatory
- end stage renal disease
- signaling pathway
- ulcerative colitis
- newly diagnosed
- ejection fraction
- induced apoptosis
- chronic kidney disease
- dna damage
- nitric oxide synthase
- peritoneal dialysis
- prognostic factors
- ischemia reperfusion injury
- high resolution
- drug delivery
- endothelial cells